Video
Author(s):
Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.
Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure (CHF) in survivors of hematopoietic cell transplantation (HCT).
According to previous data, HCT survivors have an increased risk of developing cardiovascular disease. The risk of post-HCT CHF can be attributed to pre-HCT exposure to anthracyclines.
In the trial, patients with post-HCT CHF were matched with a cohort that did not develop post-HCT CHF with regards to age at transplantation, type of transplant (autologous or allogeneic), and exposure to anthracycline. The study analyzed 77 patients with CHF and 178 patients in the control cohort who had not developed CHF.
The study found that the risk of anthracycline cardiotoxicity is modified by genes that affect free radical generation, dysregulation of iron homeostasis, and intracellular accumulation of cardiotoxic anthracyclines.
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512